How much funding has Alder raised?

Alder has raised $94.0M in total funding, most recently a Series D round.

Who are Alder's investors?

Alder's investors include Novo Holdings A/S, Delphi Ventures, H.I.G. Capital, Lundbeck A/S, TPG Biotechnology Partners, Sevin Rosen Funds.

Where is Alder headquartered?

Alder is headquartered in Bothell, Washington, United States.

Alder

Acquired

Bothell, United States · Founded 2004 · $94.0M raised

Biotech

Headquarters: Bothell, Washington
Founded: 2004
Business Model: B2B
Total Funding: $94.0M

Last Round: $38.0M Series DApr 2012
Rounds: 3
Acquisition Date: Sep 2019

About

Alder BioPharmaceuticals (now Lundbeck Seattle Biopharmaceuticals) was a Bothell, Washington-based clinical-stage biopharmaceutical company founded in 2004 that discovered, developed, and manufactured therapeutic monoclonal antibodies for migraine, cancer, pain, cardiovascular, and autoimmune/inflammatory diseases. It went public on Nasdaq in May 2014, and in September 2019 was acquired by Denmark's H. Lundbeck A/S in a deal valued at up to $1.95 billion, becoming the platform behind the migraine-prevention drug Vyepti (eptinezumab).

Summary

Alder is a Biotech company based in Bothell, United States, founded in 2004. It has raised $94.0M in total across 3 rounds, most recently a $38.0M Series D round in Apr 2012. Investors include Novo Holdings A/S, Delphi Ventures and H.I.G. Capital.